Corrigendum to “GEC-ESTRO ACROP prostate brachytherapy guidelines” [Radiother Oncol. 2022; 167: 244–251] (Radiotherapy and Oncology (2022) 167 (244–251), (S0167814022000019), (10.1016/j.radonc.2021.12.047))

Ann Henry; Bradley R. Pieters; Frank André Siebert; Peter Hoskin

doi:10.1016/j.radonc.2025.110791

Corrigendum to “GEC-ESTRO ACROP prostate brachytherapy guidelines” [Radiother Oncol. 2022; 167: 244–251] (Radiotherapy and Oncology (2022) 167 (244–251), (S0167814022000019), (10.1016/j.radonc.2021.12.047))

Ann Henry
, Bradley R. Pieters
, Frank André Siebert
, Peter Hoskin^*

^*Corresponding author for this work

Leeds Teaching Hospitals NHS Trust
Amsterdam UMC - University of Amsterdam
Universitätsklinikum Schleswig-Holstein Campus Kiel
East and North Hertfordshire NHS Trust
University of Manchester

Research output: Contribution to journal › Comment/Letter to the editor › Academic

22 Downloads (Pure)

Abstract

The authors regret that within the abovementioned article, Table 2 was published with erroneous data. The corrected table is printed below. Table 2 Planning aims and objectives of temporary HDR brachytherapy [Table presented] (*) EQD2 dose was calculated using the following concept: prescribed dose: external 25 × 2 Gy, HDR brachytherapy 1 × 15 Gy, α/β-ratio=1.5 Gy, EQD2: 50 Gy + 70.7 Gy ≈ 121 Gy. The authors apologise for any inconvenience caused.

Original language	English
Article number	110791
Journal	Radiotherapy and oncology
Volume	206
DOIs	https://doi.org/10.1016/j.radonc.2025.110791
Publication status	Published - 1 May 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.radonc.2025.110791

Corrigendum-to-gec-estro-acrop-prostate-brachytherapy-guidelines-radiother-oncol-2022-167.pdfFinal published version, 265 KBLicence: Taverne

Fingerprint

Dive into the research topics of 'Corrigendum to “GEC-ESTRO ACROP prostate brachytherapy guidelines” [Radiother Oncol. 2022; 167: 244–251] (Radiotherapy and Oncology (2022) 167 (244–251), (S0167814022000019), (10.1016/j.radonc.2021.12.047))'. Together they form a unique fingerprint.

Cite this

Henry, A., Pieters, B. R., Siebert, F. A., & Hoskin, P. (2025). Corrigendum to “GEC-ESTRO ACROP prostate brachytherapy guidelines” [Radiother Oncol. 2022; 167: 244–251] (Radiotherapy and Oncology (2022) 167 (244–251), (S0167814022000019), (10.1016/j.radonc.2021.12.047)). Radiotherapy and oncology, 206, Article 110791. https://doi.org/10.1016/j.radonc.2025.110791

@article{a7eadee163184c47ae3c34a6a40d2424,

title = "Corrigendum to “GEC-ESTRO ACROP prostate brachytherapy guidelines” [Radiother Oncol. 2022; 167: 244–251] (Radiotherapy and Oncology (2022) 167 (244–251), (S0167814022000019), (10.1016/j.radonc.2021.12.047))",

abstract = "The authors regret that within the abovementioned article, Table 2 was published with erroneous data. The corrected table is printed below. Table 2 Planning aims and objectives of temporary HDR brachytherapy [Table presented] (*) EQD2 dose was calculated using the following concept: prescribed dose: external 25 × 2 Gy, HDR brachytherapy 1 × 15 Gy, α/β-ratio=1.5 Gy, EQD2: 50 Gy + 70.7 Gy ≈ 121 Gy. The authors apologise for any inconvenience caused.",

author = "Ann Henry and Pieters, \{Bradley R.\} and Siebert, \{Frank Andr{\'e}\} and Peter Hoskin",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier B.V.",

year = "2025",

month = may,

day = "1",

doi = "10.1016/j.radonc.2025.110791",

language = "English",

volume = "206",

journal = "Radiotherapy and oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

}

Corrigendum to “GEC-ESTRO ACROP prostate brachytherapy guidelines” [Radiother Oncol. 2022; 167: 244–251] (Radiotherapy and Oncology (2022) 167 (244–251), (S0167814022000019), (10.1016/j.radonc.2021.12.047)). / Henry, Ann; Pieters, Bradley R.; Siebert, Frank André et al.
In: Radiotherapy and oncology, Vol. 206, 110791, 01.05.2025.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Corrigendum to “GEC-ESTRO ACROP prostate brachytherapy guidelines” [Radiother Oncol. 2022; 167

T2 - 244–251] (Radiotherapy and Oncology (2022) 167 (244–251), (S0167814022000019), (10.1016/j.radonc.2021.12.047))

AU - Henry, Ann

AU - Pieters, Bradley R.

AU - Siebert, Frank André

AU - Hoskin, Peter

PY - 2025/5/1

Y1 - 2025/5/1

N2 - The authors regret that within the abovementioned article, Table 2 was published with erroneous data. The corrected table is printed below. Table 2 Planning aims and objectives of temporary HDR brachytherapy [Table presented] (*) EQD2 dose was calculated using the following concept: prescribed dose: external 25 × 2 Gy, HDR brachytherapy 1 × 15 Gy, α/β-ratio=1.5 Gy, EQD2: 50 Gy + 70.7 Gy ≈ 121 Gy. The authors apologise for any inconvenience caused.

AB - The authors regret that within the abovementioned article, Table 2 was published with erroneous data. The corrected table is printed below. Table 2 Planning aims and objectives of temporary HDR brachytherapy [Table presented] (*) EQD2 dose was calculated using the following concept: prescribed dose: external 25 × 2 Gy, HDR brachytherapy 1 × 15 Gy, α/β-ratio=1.5 Gy, EQD2: 50 Gy + 70.7 Gy ≈ 121 Gy. The authors apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85217897910

U2 - 10.1016/j.radonc.2025.110791

DO - 10.1016/j.radonc.2025.110791

M3 - Comment/Letter to the editor

C2 - 39983546

SN - 0167-8140

VL - 206

JO - Radiotherapy and oncology

JF - Radiotherapy and oncology

M1 - 110791

ER -

Corrigendum to “GEC-ESTRO ACROP prostate brachytherapy guidelines” [Radiother Oncol. 2022; 167: 244–251] (Radiotherapy and Oncology (2022) 167 (244–251), (S0167814022000019), (10.1016/j.radonc.2021.12.047))

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this